The producer of ready-mixed concrete and asphalt said a NAFTA tribunal found Mexico in violation over the country's repudiation of an agreement to unlock a portion of Vulcan's aggregates reserves, and ...

Union Pacific and Norfolk Southern are stepping up efforts to convince regulators to approve their $71.5 billion merger, adding commitments to ensure the deal will provide faster, more reliable ...

Celestica raised its forecast for the year, citing expectations for stronger customer demand after sales jumped in its latest quarter.

Nucor logged higher profit in its second quarter, driven by the strength of its steel mills segment. The steel manufacturer posted a profit of $1.16 billion, or $5.04 a share, compared with $603 ...

Amkor Technology logged an increase in sales and profit in the second quarter, as the company expanded partnerships and capitalized on the artificial intelligence momentum.

We love each other deeply, but not in a husband-and-wife sense. We are not romantically involved. I own my home outright, have no children or other dependents, and my closest relatives are my siblings ...

Orange SA is partnering with infrastructure investor Morrison to form a data center company located in France. The French telecommunications operator said Monday the joint venture would support and ...

SpaceX’s earnings report next week could unleash a further wave of selling, as some insiders will soon be able to unload ...

The U.S. released 3.7 million bbl from the Strategic Petroleum Reserve, with stockpiles falling below the 310 million bbl mark for the first time in more than 43 years.

Crude futures fell midday Monday after the U.S. paused plans to escalate military action against Iran, easing concerns over potential supply disruptions. As of 11:20 a.m. ET, the September ICE Brent ...

Shares of Legend Biotech fell after the cell-therapy company said its Chief Executive Ying Huang has resigned. The stock slipped 15% to $18.89 in recent trading, and is down more than 13% since the ...

MapLight Therapeutics shares plunged to a 52-week low Monday morning after investors focused on mixed results from the company's Phase 2 schizophrenia trial, in which only one of two dosing regimens ...